Related papers: Predicting Tau Accumulation in Cerebral Cortex wit…
Alzheimer's disease (AD) is a progressive and incurable neurodegenerative disease which destroys brain cells and causes loss to patient's memory. An early detection can prevent the patient from further damage of the brain cells and hence…
Alzheimer's disease (AD) is an irreversible devastative neurodegenerative disorder associated with progressive impairment of memory and cognitive functions. Its early diagnosis is crucial for the development of possible future treatment…
Unveiling pathological brain changes associated with Alzheimer's disease (AD) is a challenging task especially that people do not show symptoms of dementia until it is late. Over the past years, neuroimaging techniques paved the way for…
INTRODUCTION: Previous studies have applied normative modeling on a single neuroimaging modality to investigate Alzheimer Disease (AD) heterogeneity. We employed a deep learning-based multimodal normative framework to analyze…
In this study, we proposed and evaluated a graph-based framework to assess variations in Alzheimer's disease (AD) neuropathologies, focusing on classic (cAD) and rapid (rpAD) progression forms. Histopathological images are converted into…
Alzheimer's disease (AD) is an irreversible neurodegenerative disorder that progressively destroys memory and other cognitive domains of the brain. While effective therapeutic management of AD is still in development, it seems reasonable to…
Alzheimer's disease is the most common dementia leading to an irreversible neurodegenerative process. To date, subject revealed advanced brain structural alterations when the diagnosis is established. Therefore, an earlier diagnosis of this…
Alzheimer's disease (AD) is a neurodegenerative disorder and the most common cause of dementia in the elderly. The extracellular accumulation of amyloid-$\beta$ (A$\beta$) in senile plaques is a principal event in the pathogenesis and there…
Early and accurate diagnosis of Alzheimer's disease (AD) and its prodromal period mild cognitive impairment (MCI) is essential for the delayed disease progression and the improved quality of patients'life. The emerging computer-aided…
Three major biomarkers: beta-amyloid (A), pathologic tau (T), and neurodegeneration (N), are recognized as valid proxies for neuropathologic changes of Alzheimer's disease. While there are extensive studies on cerebrospinal fluids…
Objectives: The objectives of this narrative review are to summarize the current state of AI applications in neuroimaging for early Alzheimer's disease (AD) prediction and to highlight the potential of AI techniques in improving early AD…
Amyloid-$\beta$ (A$\beta$) plaques in conjunction with hyperphosphorylated tau proteins in the form of neurofibrillary tangles are the two neuropathological hallmarks of Alzheimer's disease. It is well-known that the identification of…
Alzheimer's disease (AD) is a neurodegenerative disease that affects nearly 50 million individuals across the globe and is one of the leading causes of deaths globally. It is projected that by 2050, the number of people affected by the…
Alzheimer s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, where early detection is essential for timely intervention and improved patient outcomes. Traditional diagnostic methods are…
Tau positron emission tomography (tau-PET) is an important in vivo biomarker of Alzheimer's disease, but its cost, limited availability, and acquisition burden restrict broad clinical use. This work proposes an interpretable multimodal…
In recent years, deep learning models have been applied to neuroimaging data for early diagnosis of Alzheimer's disease (AD). Structural magnetic resonance imaging (sMRI) and positron emission tomography (PET) images provide structural and…
Alzheimer's disease (AD) confirmation often relies on positron emission tomography (PET) or cerebrospinal fluid (CSF) analysis, which are costly and invasive. Consequently, structural MRI biomarkers such as cortical thickness (CT) are…
Tau positron emission tomography (PET) is a critical diagnostic modality for Alzheimer's disease (AD) because it visualizes and quantifies neurofibrillary tangles, a hallmark of AD pathology. However, its widespread clinical adoption is…
Alzheimer's disease is a progressive neurological disorder characterized by cognitive impairment and memory loss. With the increasing aging population, the incidence of AD is continuously rising, making early diagnosis and intervention an…
The preclinical stage of many neurodegenerative diseases can span decades before symptoms become apparent. Understanding the sequence of preclinical biomarker changes provides a critical opportunity for early diagnosis and effective…